Enliven Therapeutics ELVN Enterprise value

Enterprise value at other companies

Bristol-Myers SquibbBMY

$152.27B+14.9%

PfizerPFE

$222.4B+9.2%

ImmunityBio, Inc.IBRX

$8.16B+187%

Iovance Biotherapeutics, Inc.IOVA

$1.79B+227%

Syndax PharmaceuticalsSNDX

$2.28B+84.0%

Cullinan Therapeutics, Inc.CGEM

$1.04B+166%

FAQ

What is Enliven Therapeutics's enterprise value?

Enliven Therapeutics (ELVN) reported enterprise value of $2.21B in Q1 2026.

How has Enliven Therapeutics's enterprise value changed year-over-year?

Enliven Therapeutics's enterprise value increased by 156.2% year-over-year, from $863.4M to $2.21B.

What is the long-term trend for Enliven Therapeutics's enterprise value?

Over 2 years (2021 to 2025), Enliven Therapeutics's enterprise value has grown at a 742.5% compound annual growth rate (CAGR), from $11.49M to $815.45M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.